| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $2.9M | 0.00% | 28.90K | −8.5% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a MLAB trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 13, 2026 | Alltoft Jennifer SadieDirector | — | 2.8K | — |
| Aug 13, 2026 | Sullivan John JamesDirector | — | 2.8K | — |
| Aug 13, 2026 | Tripeny R TonyDirector | — | 2.8K | — |
| Aug 13, 2026 | Capone Mark ChristopherDirector | — | 2.8K | — |
| Aug 13, 2026 | Hall ShannonDirector | — | 2.8K | — |
| Aug 13, 2026 | Ladiwala Shiraz ShabanaliDirector | — | 3.8K | — |
| Aug 12, 2026 | Sullivan John JamesDirector | Sale at price 112.80 per share. | 7.1K | $800.09K |
| Aug 12, 2026 | Tripeny R TonyDirector | Purchase at price 113.69 per share. | 900 | $102.32K |
| Aug 12, 2026 | Kadia SiddharthaChief Executive Officer | Purchase at price 112.80 per share. | 7.1K | $800.09K |
| Jun 21, 2026 | Sakys John VChief Financial Officer | Sale at price 89.50 per share. | 2.8K | $253.02K |
| Jun 21, 2026 | Archbold Brian DavidOfficer | Sale at price 89.50 per share. | 2.5K | $225.19K |
| Jun 21, 2026 | Crennen Lyndsey ElizabethOfficer | Sale at price 89.50 per share. | 442 | $39.56K |
| Jun 17, 2026 | Sakys John VChief Financial Officer | Stock Award(Grant) at price 95.10 per share. | 2.3K | $217.02K |
| Jun 17, 2026 | Archbold Brian DavidOfficer | Stock Award(Grant) at price 95.10 per share. | 1.9K | $176.79K |
| Jun 17, 2026 | Crennen Lyndsey ElizabethOfficer | Stock Award(Grant) at price 95.10 per share. | 263 | $25.01K |
| Jun 17, 2026 | Archbold Brian DavidOfficer | — | 3.3K | — |
| Jun 17, 2026 | Crennen Lyndsey ElizabethOfficer | — | 726 | — |
| Jun 17, 2026 | Sakys John VChief Financial Officer | — | 3.8K | — |
| Jun 15, 2026 | Sakys John VChief Financial Officer | Sale at price 101.27 per share. | 1.2K | $123.85K |
| Jun 15, 2026 | Archbold Brian DavidOfficer | Sale at price 101.27 per share. | 1.2K | $116.56K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.3 | 22.6 | -8.4 | 13.1 | 2.0 | -2.4 | 1.3 | 26.8 | 1.6 | -1.5 | +63.0% | ||
| 2025 | 4.4 | 1.2 | -14.9 | -2.9 | -12.7 | -6.4 | -18.8 | -11.4 | -1.1 | 7.3 | 11.6 | -2.1 | −40.5% |
| 2024 | -12.6 | 19.2 | 0.5 | -3.3 | -9.8 | -9.3 | 32.0 | 16.7 | -2.9 | -12.2 | 2.7 | 12.6 | +25.9% |
| 2023 | 17.0 | -9.3 | -1.0 | -4.7 | -22.2 | -0.8 | 0.1 | 11.4 | -26.7 | -10.7 | -9.0 | 22.7 | −37.0% |
| 2022 | -13.3 | -10.2 | -0.2 | -16.2 | -2.1 | -2.5 | 4.6 | -19.9 | -17.6 | -6.1 | 28.0 | -1.7 | −49.3% |
| 2021 | -3.3 | -1.9 | -10.4 | 2.1 | -1.0 | 10.2 | 8.6 | -9.4 | 13.3 | 1.1 | 1.0 | 6.3 | +14.5% |
| 2020 | 5.2 | -8.8 | -5.5 | 5.3 | 11.0 | -18.0 | 9.3 | 3.8 | 3.6 | 2.6 | 4.0 | 5.5 | +14.9% |
| 2019 | 8.7 | 1.6 | 0.2 | 2.7 | 5.5 | -2.1 | 3.0 | -12.1 | 7.5 | -4.2 | 2.8 | 6.5 | +19.7% |
| 2018 | 13.8 | -7.4 | 13.3 | 13.4 | -5.5 | 32.7 | -4.2 | -0.7 | -7.5 | -1.6 | 21.2 | -5.9 | +67.7% |
| 2017 | -2.9 | 4.9 | -1.9 | 14.0 | 11.8 | -8.3 | 0.9 | -5.5 | 9.3 | 6.8 | -15.6 | -7.6 | +1.3% |
| 2016 | 4.5 | -13.5 | 7.1 | 4.6 | -2.1 | 24.7 | -6.0 | -2.8 | 1.8 | 10.4 | -1.7 | -1.1 | +23.4% |
| 2015 | -1.5 | -3.0 | -2.3 | 17.6 | 4.0 | 0.7 | 16.5 | 4.7 | 2.8 | 0.4 | -3.3 | -8.0 | +28.7% |
| 2014 | 2.2 | 8.9 | 3.3 | -5.0 | -6.6 | 4.9 | -8.9 | -6.9 | -18.8 | 32.2 | -3.5 | 4.9 | −1.6% |
| 2013 | 3.8 | 2.1 | -0.5 | -6.5 | 7.3 | 2.2 | 20.6 | -0.3 | 3.9 | 3.0 | 18.9 | -5.1 | +56.8% |
| 2012 | 7.3 | 20.3 | -7.8 | 0.6 | -9.9 | 3.9 | -0.4 | 1.6 | 2.9 | 0.8 | -2.9 | 5.8 | +20.9% |
| 2011 | -5.3 | 6.4 | -4.8 | 6.6 | -1.3 | 4.3 | 4.7 | 1.4 | 5.4 | 6.2 | 9.1 | 1.2 | +38.1% |
| 2010 | 5.0 | -4.5 | 0.2 | -0.5 | -11.3 | 5.0 | -0.4 | -5.1 | 1.2 | 8.7 | 5.4 | 13.9 | +16.1% |
| 2009 | 14.9 | -10.4 | -11.2 | 25.0 | 0.0 | -1.9 | 12.2 | 0.1 | 4.0 | 4.8 | 0.2 | 7.5 | +47.7% |
| 2008 | -9.2 | 5.8 | -8.6 | -0.6 | -7.8 | 19.4 | -12.3 | -2.6 | 3.7 | -20.0 | 8.8 | -5.4 | −30.0% |
| 2007 | 12.2 | -6.5 | -4.4 | 0.8 | 28.7 | -5.5 | 3.7 | -8.5 | -6.2 | 8.6 | 10.5 | 0.4 | +32.0% |
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides sterility assurance testing and laboratory services to the dental and pharmaceutical industries. The Biopharmaceutical Development segment develops, manufactures, sells, and services automated systems for protein analysis (immunoassays) and peptide synthesis solutions. Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for hereditary disease screenings, pharmacogenetics, oncology related applications, and toxicology research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; and PurePep Symphony and Chorus instruments for peptide synthesis. Its Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as renal care, gas flow, environmental and process monitoring, and torque testing in pharmaceutical, laboratory, medical device, manufacturing, industrial, and environmental applications. This segment's products include continuous monitoring systems, data loggers, and torque testing systems under the DialyGuard, DryCal, DataTrace, and ViewPoint brands. Mesa Laboratories, Inc. was incorporated in 1982 and is headquartered in Lakewood, Colorado.
Buy / hold / sell counts